Drug Detail:Darolutamide (systemic) (monograph) (Nubeqa)
Drug Class:
Usual Adult Dose for Prostate Cancer
600 mg orally 2 times a day
Comments:
- Patients receiving this drug should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
Use: For nonmetastatic castration resistant prostate cancer (nmCRPC)
Renal Dose Adjustments
Mild to moderate renal impairment (CrCl 30 to 89 mL/min): No adjustment recommended.
Severe renal impairment (CrCl 15 to 29 mL/min) who are not receiving hemodialysis: 300 mg orally 2 times a day
End stage renal disease (CrCl 15 mL/min or less): Data not available
Liver Dose Adjustments
Mild (Child-Pugh A) hepatic impairment: No adjustment recommended.
Moderate (Child-Pugh B) hepatic impairment: 300 mg orally 2 times daily
Severe (Child-Pugh C) hepatic impairment: Data not available
Dose Adjustments
Grade 3 or greater toxicity or an intolerable adverse reaction: Withhold therapy or reduce to the dose to 300 mg 2 times a day until symptoms improve; then resume therapy at 600 mg orally 2 times a day.
Dose reduction below 300 mg orally 2 times a day is not recommended.
Precautions
CONTRAINDICATIONS:
- None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug should be taken with food.
- Swallow tablets whole; do not divide, crush, or chew.
- If a dose is missed it should be taken as soon as it is remembered prior to the next scheduled dose; do not take 2 doses together to make up for a missed dose.
Storage requirements:
- Store at 20C to 25C (68F to 77F); excursions permitted between 15C and 30C (59F and 86F).
- Keep the bottle tightly closed after first opening.